Skip to content

Study · Other design · n = 38 · 2016

6 results

Oxytocin's inhibitory effect on food intake is stronger in obese than normal-weight men.

Thienel M, Fritsche A, Heinrichs M, Peter A, Ewers M, Lehnert H, Born J, Hallschmid M

International journal of obesity (2005)24 Aug 2016Cited by 129 (Europe PMC)

PMID27553712 (opens in a new tab)PMCIDPMC5116063 (opens in a new tab)DOI10.1038/ijo.2016.149 (opens in a new tab)PepBankPUB-27553712
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanOther designEfficacy outcome

    In obese and normal-weight men, intranasal oxytocin reduced snack consumption versus placebo.

    In plain wordsIn men with and without obesity, oxytocin reduced snack eating compared with placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseReward-driven snack consumption
    Study

    n = 38

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    and led to a reduction in snack consumption in both groups
    2 context sentences
    Summary · context
    We compared the effect of central nervous oxytocin administration (24 IU) via the intranasal route on ingestive behaviour and metabolic function in 18 young obese men with the results in a group of 20 normal-weight men.
    Summary · context
    In double-blind, placebo-controlled experiments, ad libitum food intake from a test buffet was examined in fasted subjects 45 min after oxytocin administration, followed by the assessment of postprandial, reward-driven snack intake.
  2. 02HumanOther designEfficacy outcome

    In obese and normal-weight men, energy expenditure remained generally unaffected by intranasal oxytocin.

    In plain wordsIn men with and without obesity, oxytocin did not generally change energy use compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeEnergy expenditure
    Study

    n = 38

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    whereas energy expenditure remained generally unaffected.
    3 context sentences
    Summary · context
    Energy expenditure was repeatedly assessed by indirect calorimetry and blood was sampled to determine concentrations of blood glucose and hormones.
    Summary · context
    We compared the effect of central nervous oxytocin administration (24 IU) via the intranasal route on ingestive behaviour and metabolic function in 18 young obese men with the results in a group of 20 normal-weight men.
    Summary · context
    In double-blind, placebo-controlled experiments, ad libitum food intake from a test buffet was examined in fasted subjects 45 min after oxytocin administration, followed by the assessment of postprandial, reward-driven snack intake.
  3. 03HumanOther designEfficacy outcome

    In obese and normal-weight men, intranasal oxytocin blunted hypothalamic-pituitary-adrenal axis secretion versus placebo.

    In plain wordsIn men with and without obesity, oxytocin dampened stress hormone release compared with placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseHypothalamic-pituitary-adrenal axis secretion
    Study

    n = 38

    Comparator
    Placebo
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    Hypothalamic-pituitary-adrenal axis secretion and the postprandial rise in plasma glucose were blunted by oxytocin in both groups
    2 context sentences
    Summary · context
    We compared the effect of central nervous oxytocin administration (24 IU) via the intranasal route on ingestive behaviour and metabolic function in 18 young obese men with the results in a group of 20 normal-weight men.
    Summary · context
    In double-blind, placebo-controlled experiments, ad libitum food intake from a test buffet was examined in fasted subjects 45 min after oxytocin administration, followed by the assessment of postprandial, reward-driven snack intake.
  4. 04HumanOther designEfficacy outcome

    In obese and normal-weight men, intranasal oxytocin blunted the postprandial rise in plasma glucose versus placebo.

    In plain wordsIn men with and without obesity, oxytocin reduced the blood sugar rise after a meal compared with placebo.

    Peptide
    Oxytocin
    Outcome
    DecreasePostprandial rise in plasma glucose
    Study

    n = 38

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    Hypothalamic-pituitary-adrenal axis secretion and the postprandial rise in plasma glucose were blunted by oxytocin in both groups.
    2 context sentences
    Summary · context
    We compared the effect of central nervous oxytocin administration (24 IU) via the intranasal route on ingestive behaviour and metabolic function in 18 young obese men with the results in a group of 20 normal-weight men.
    Summary · context
    In double-blind, placebo-controlled experiments, ad libitum food intake from a test buffet was examined in fasted subjects 45 min after oxytocin administration, followed by the assessment of postprandial, reward-driven snack intake.
  5. 05HumanOther designEfficacy outcome

    In normal-weight men, intranasal oxytocin did not reduce hunger-driven food intake in the fasted state versus placebo.

    In plain wordsIn normal-weight men, oxytocin did not reduce food eaten when hungry, compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeHunger-driven food intake in the fasted state, normal-weight men
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    Oxytocin markedly reduced hunger-driven food intake in the fasted state in obese but not in normal-weight men
    2 context sentences
    Summary · context
    We compared the effect of central nervous oxytocin administration (24 IU) via the intranasal route on ingestive behaviour and metabolic function in 18 young obese men with the results in a group of 20 normal-weight men.
    Summary · context
    In double-blind, placebo-controlled experiments, ad libitum food intake from a test buffet was examined in fasted subjects 45 min after oxytocin administration, followed by the assessment of postprandial, reward-driven snack intake.
  6. 06HumanOther designEfficacy outcome

    In young obese men, intranasal oxytocin markedly reduced hunger-driven food intake in the fasted state versus placebo.

    In plain wordsIn young men with obesity, oxytocin sharply reduced food eaten when hungry, compared with placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseHunger-driven food intake in the fasted state, obese men
    Study

    n = 18

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    Oxytocin markedly reduced hunger-driven food intake in the fasted state in obese
    2 context sentences
    Summary · context
    We compared the effect of central nervous oxytocin administration (24 IU) via the intranasal route on ingestive behaviour and metabolic function in 18 young obese men with the results in a group of 20 normal-weight men.
    Summary · context
    In double-blind, placebo-controlled experiments, ad libitum food intake from a test buffet was examined in fasted subjects 45 min after oxytocin administration, followed by the assessment of postprandial, reward-driven snack intake.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.